<DOC>
	<DOCNO>NCT01385150</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor identify lean biomarkers related cancer . PURPOSE : This research study study biomarkers blood sample patient acute myeloid leukemia .</brief_summary>
	<brief_title>Biomarkers Blood Samples From Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine serum 2-hydroxyglutarate ( 2HG ) detect acute myeloid leukemia ( AML ) patient isocitrate dehydrogenase ( IDH ) mutation . Secondary - To determine level serum 2HG impact leukemia-free survival ( LFS ) . - To determine level serum 2HG impact overall survival ( OS ) . - To determine serum 2HG undetectable time document clinical remission ( CR ) IDH-mutated patient . OUTLINE : Archived serum sample analyze 2-hydroxyglutarate expression reverse-phase liquid chromatography couple mass spectrometry . Results compare presence absence IDH mutation , patient ' clinical outcome , well age , sex , white blood cell count diagnosis , platelet count , bone marrow blast percentage diagnosis , circulate ( serum ) percentage diagnosis , cytogenetic risk group , presence FLT3 , NPMN1 , and/or TET2 mutation , specific IDH mutation , randomization treatment group allocation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute myeloid leukemia ( AML ) Newly diagnose AML Serum sample patient enrol ECOG1900 clinical trial 2002 2008 Patients without isocitrate dehydrogenase ( IDH ) mutation PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Received 2 different dos standard induction chemotherapy ECOG1900</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>